The risk of psychosis associated with use of amphetamine for attention-deficit/hyperactivity disorde...

The Food and Drug Administration has approved Jornay PM (extended-release methylphenidate capsules) ...

Welcome to New York City! APA’s 2018 Annual Meeting began in New York today. From now through May 9,...

Stimulants are a preferred option for treating attention-deficit/hyperactivity disorder (ADHD), but ...

Methylphenidate appears to improve apathy in patients with mild Alzheimer’s disease (AD), according ...

Treating patients experiencing cognitive impairments following a traumatic brain injury (TBI) with a...

Determining the best medications for patients with co-occurring bipolar disorder and attention-defic...

Findings from a study published in BMJ Open Access shows that some children and adolescents who are ...

Youth who are taking medications prescribed for attention-deficit/hyperactivity disorder (ADHD) exhi...